Scientific publications

Oral immunotherapy using polymeric nanoparticles loaded with peanut proteins in a murine model of fatal anaphylaxis

Nov 9, 2017 | Magazine: Immunotherapy

Gamazo C (1), García-Azpíroz M (1), Souza Rebouças J (1,2), Gastaminza G (3), Ferrer M (3), Irache JM (4). (1) Department of Microbiology, University of Navarra, Instituto de Investigación Sanitaria de Navarra (Idisna), C/Irunlarrea, 1; 31080 - Pamplona, Spain.
(2) Laboratory of Microbiology & Immunoregulation, Gonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil.
(3) Department of Allergology & Clinical Immunology, Clínica Universidad de Navarra, Navarra, Spain.
(4) Department of Pharmacy & Pharmaceutical Technology, University of Navarra, Navarra, Spain.


Peanut allergy is the most common cause of anaphylaxis and food-related death. However, there is currently no approved immunotherapy treatment. Hence, this warrants the need for relevant and convenient animal models to test for adequate immunotherapies.


In this study, we compared three mouse strains: CD1, BALB/c and C57, to select a model of peanut allergy. After that, we conducted then a therapeutic study using an immunogenic peanut extract encapsulated in nanoparticles made with polymer Gantrez® following the solvent displacement method.


After implementing a dosing schedule with oral commercial peanut butter, the antibody responses, cytokine profiles and, above all, the anaphylaxis induced after a challenge with peanut proteins, showed that the outbred CD1 strain was the most susceptible to peanut sensitization. CD1 sensitized mice were orally immunized with three doses of the nanoparticle formulation capable of protecting them against the severe anaphylactic symptoms induced by the peanut challenge.

CITATION  Immunotherapy. 2017 Nov;9(15):1205-1217. doi: 10.2217/imt-2017-0111.